The experimental, trivalent vaccine consists of the co-administration of two live-attenuated bacteria, the Peru-15pCTB vaccine candidate that forms the basis of Avant’s investigational combination ETEC/cholera vaccine, and Avant’s investigational typhoid fever vaccine, Ty800.
Avant has also said that the National Institutes of Health will be sponsoring a Phase I clinical trial of the Peru-15pCTB vaccine combining protection against ETEC and cholera in first quarter of 2008, and Avant’s Ty800 is currently undergoing Phase II clinical testing.
Una Ryan,president and CEO of AVANT Immunotherapeutics, said: “If the results of these current clinical studies are successful, the preclinical data presented today pave the way for initial human clinical testing of a trivalent super-enteric vaccine.”